Oncotest is a CRO specializing in preclinical oncology services
As a pioneer in the field of patient derived tumor xenografts (PDX), Oncotest provides tailored solutions to the problems faced by preclinical oncology researchers. We assist them with the identification of the best drug candidates and the validation of their targets and deliver in-depth bioinformatics analyses, laying the groundwork for the successful planning of clinical trials.
The core of our integrated profiling approach is our constantly growing PDX collection that was started 30 years ago by company founder Prof. Dr. H.-H. Fiebig. Our diverse tumor model collection enables us to recommend the right assays and models to answer our customers’ questions. Why do we trust in PDX models?
Our experienced team of scientists and skilled technicians take pride in the consistent high quality of our data and we greatly value the trust that our customers continue to place in us after more than two decades in the field.
With our AAALAC accredited facilities with IVC system, separate model development unit, large cage capacity of over 14,500 mice and proprietary electronic measurement system with an integrated database and by continuously maintaining important PDX models in mice, we are able to provide the highest standard of testing within a reasonable timeframe.